Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Phase 2

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

NCT06101134 · tracked via the Priya Life Science Spain tracker
Phase
Phase 2
Started
2023-11-06
Last updated
2026-09-14

Condition(s) studied

Melanoma

Investigational drug(s) / intervention(s)

relatlimab+nivolumabAll Relatlimab trials (47) →All Nivolumab trials (278) →relatlimab+nivolumab+rHuPH20All Relatlimab trials (47) →All Nivolumab trials (278) →All Phesgo trials (15) →nivolumab →nivolumab+rHuPH20All Nivolumab trials (278) →All Phesgo trials (15) →

relatlimab+nivolumab: Specified dose on specified days

relatlimab+nivolumab+rHuPH20: Specified dose on specified days

nivolumab: Specified dose on specified days

nivolumab+rHuPH20: Specified dose on specified days

Study summary

The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration. This study will also generate safety data which will further characterize the safety profile of patients switching the route of administration from intravenous (IV) to SC.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Must have either metastatic melanoma and have not had previous treatment for their cancer, or resected melanoma and have had the cancer removed fully with surgery no later than 12 weeks before the start of treatment and confirmed free of disease * Must have a low level of disability and cancer that is considered advanced for metastatic melanoma and at risk for becoming advanced (intermediate) or advanced for resected melanoma Exclusion Criteria: * Must not have any brain cancer/disease treated with radiation, any cancer in the eyes or mucous membranes (cells that cover inside surface of parts of the body and keep it moist), any autoimmune disease, or any condition that is being treated with steroids for inflammation (corticosteroids) or medication to decrease the body's immune system response (immunosuppressive drugs) Other protocol-defined inclusion/exclusion criteria apply.

Primary outcome measure(s)

  • Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 Dose — Cycle 4 Day 1 (each cycle consist of 4 weeks)
    PEPQ included 7 items 1. Pain or Discomfort (rated on 1 to 10 scale), 2. Length of time related to administration 3. Length of time related to administration impact amount of time to speak to doctor or nurse about illness or concern 4. Length of time for administration impact time to interact or socialize with other individuals 5. Convenience 6. Satisfaction 7. Choice of which route of administration would be preferred. 95% CI exact confidence interval was reported.

Trial sites (31)

FacilityCityRegionStatus
Local Institution - 0007 Anchorage Alaska
Local Institution - 0013 Phoenix Arizona
Local Institution - 0010 San Francisco California
Local Institution - 0034 Atlanta Georgia
Local Institution - 0032 Edgewood Kentucky
Local Institution - 0028 Albuquerque New Mexico
Local Institution - 0037 Edmonds Washington
Local Institution - 0036 Issaquah Washington
Local Institution - 0030 Seattle Washington
Local Institution - 0015 Las Condes Santiago Metropolitan
Local Institution - 0005 Concepción Chile
Local Institution - 0019 Thessaloniki B
Local Institution - 0014 Athens I
Local Institution - 0029 Marousi I
Local Institution - 0023 Holargos, Athens Greece
Local Institution - 0008 Piraeus Greece
Local Institution - 0033 Thessaloniki Greece
Local Institution - 0017 Bergamo BG
Local Institution - 0035 Meldola FC
Local Institution - 0018 Milan MI
Local Institution - 0012 Padova PD
Local Institution - 0021 Roma RM
Local Institution - 0004 Torino TO
Local Institution - 0026 Naples Italy
Local Institution - 0011 Barcelona B
Local Institution - 0022 Barcelona B
Local Institution - 0009 Cartagena MU
Local Institution - 0020 Badalona Spain
Local Institution - 0027 Cantabria Spain
Local Institution - 0003 San Pedro Alcántara, Málaga Spain
Local Institution - 0006 Seville Spain
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06101134 on ClinicalTrials.gov ↗ ← All trials in Spain